ROCKET PHARMACEUTICALS, INC. (RCKT) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $411.6K sold). Latest close $2.11 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.
RTW Investments · Maverick Capital · RTW Investments — 3 tracked funds hold RCKT. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 5 sales ($411.6K). Insider trading
Wave Life Sciences, Inc. (WVE) · Abivax S.A. (ABVX) · BELITE BIO, INC (BLTE) · REPLIGEN CORP (RGEN) · INSMED Inc (INSM) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| RTW Investments | 0.52% | 17,687,772 | HELD Q3 filed Nov 16 |
| Maverick Capital | 0.12% | 3,923,963 | ADDED (+10.0%) Q3 filed Nov 16 |
| RTW Investments | <0.01% | 350,000 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -40.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 180 of 8,857 filers |
| Long-only filers among them | 180 |
| Change vs 2026 Q1 | -12 net · 175 entered · 187 exited |
| Shares reported, all filers | 99,674,505 |
| Reported value, all filers | $341.5M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $0 |
| Net income · FY2025 | $-223.1M |
| Total assets · FY2025 | $330.4M |
| Shares outstanding | 109,774,597 |
| Market cap (at latest close) | $231.6M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 16,281,767 |
| Share of shares outstanding | 14.83% |
| Days to cover | 6.68 |
Shares short at recent settlements — Jul 31, 2026: 15.5M · Aug 14, 2026: 14.4M · Aug 31, 2026: 14.7M · Sep 15, 2026: 14.8M · Sep 30, 2026: 15.0M · Oct 15, 2026: 16.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 60 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 29K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 60.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 5 sales by 3 insiders ($411.6K).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Shah Gaurav | CEO | Sell | 3,020 | $2.25 | $6.8K | SEC filing |
| Nov 13, 2026 | Wilson Martin | General Counsel | Sell | 4,087 | $2.25 | $9.2K | SEC filing |
| Nov 9, 2026 | Chaudhuri Sarbani | See Remarks | Sell | 4,872 | $2.33 | $11.3K | SEC filing |
| Nov 5, 2026 | Wilson Martin | General Counsel | Sell | 53,389 | $2.39 | $127.8K | SEC filing |
| Sep 11, 2026 | Wilson Martin | General Counsel | Sell | 75,364 | $3.40 | $256.5K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Militello John | Former Officer | 6,897 | $22.7K | Sep 15, 2026 | SEC filing |
| Sep 14, 2026 | Militello John | Former Officer | 6,857 | $22.7K | Sep 14, 2026 | SEC filing |
| Sep 11, 2026 | Wilson Martin | Officer | 75,364 | $256.5K | Sep 11, 2026 | SEC filing |
| Sep 11, 2026 | Militello John | Former Officer | 8,923 | $30.4K | Sep 11, 2026 | SEC filing |
| Aug 18, 2026 | Shah Gaurav | Officer, Director | 2,293 | $7.8K | Aug 18, 2026 | SEC filing |
| Aug 18, 2026 | Wilson Martin | Officer | 631 | $2.1K | Aug 18, 2026 | SEC filing |
| Aug 18, 2026 | Militello John | Former Officer | 1,252 | $4.2K | Aug 18, 2026 | SEC filing |
| Aug 13, 2026 | Wilson Martin | Officer | 3,493 | $11.8K | Aug 13, 2026 | SEC filing |
| Aug 13, 2026 | Shah Gaurav | Officer, Director | 2,837 | $9.6K | Aug 13, 2026 | SEC filing |
| Aug 11, 2026 | Stevens Christopher James | Officer | 36,658 | $128.3K | Aug 11, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Vanguard Portfolio Management | SC 13G | 5,847,541 | 5.3% | Jun 30, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 13, 2026 | Maverick Capital, Ltd. | SC 13G/A | 2,513,110 | 2.3% | Dec 31, 2025 | SEC filing |
| Jan 30, 2026 | The Vanguard Group | SC 13G/A | 8,544,423 | 7.9% | Dec 31, 2025 | SEC filing |
| Aug 14, 2025 | Maverick Capital, Ltd. | SC 13G/A | 8,363,813 | 7.8% | Jun 30, 2025 | SEC filing |
| Jun 5, 2025 | Wellington Management Group LLP | SC 13G/A | 1,004,476 | 0.9% | May 30, 2025 | SEC filing |
| May 7, 2025 | Wellington Management Group LLP | SC 13G/A | 7,151,721 | 6.7% | Apr 30, 2025 | SEC filing |
| May 7, 2025 | Wellington Management Group LLP | SC 13G/A | 12,626,491 | 11.8% | Mar 31, 2025 | SEC filing |
| Apr 14, 2025 | Maverick Capital, Ltd. | SC 13G | 5,547,175 | 5.2% | Apr 7, 2025 | SEC filing |
| Feb 10, 2025 | Wellington Management Group LLP | SC 13G/A | 13,995,177 | 13.4% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 22 Lobbying Disclosure Act filings named this company as client, 2019–2026; most common issues: Health Issues (7), Immigration (5), Pharmacy (2).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -10.24 · Working capital / assets: 0.49 · Retained earnings / assets: -4.36 · EBIT / assets: -0.70 · Equity / liabilities: 5.21
· Excess Accruals (Sloan) — Accruals ratio: -41.4% · Net income: $-223.1M · Operating cash flow: $-190.0M · Investing cash flow: $103.8M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Share count tripled (3x) | 1 | 0.0% | -26.8% | -4.6% | -22.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold RCKT — ranked by lift, the co-holding pattern described in Methodology: Wave Life Sciences, Inc. (WVE) · Abivax S.A. (ABVX) · BELITE BIO, INC (BLTE) · REPLIGEN CORP (RGEN) · INSMED Inc (INSM) · uniQure N.V. (QURE) · Natera, Inc. (NTRA).
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 6, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 15, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Wave Life Sciences, Inc. (WVE) · Track Record: how the signals scored · Practice timing on RCKT
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.